Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ohmefentanyl is an extremely potent synthetic opioid analgesic belonging to the fentanyl family. It acts as a highly selective agonist of the μ-opioid receptor, producing profound analgesia and effects similar to other opioids but at much lower doses. Ohmefentanyl is notable for its extraordinary potency—mouse studies show it can be up to 28 times more powerful than fentanyl and approximately 6,300 times more potent than morphine. The compound has three stereogenic centers, resulting in eight possible stereoisomers (F9201–F9208), each with distinct pharmacological profiles; some analogues are even more potent than ohmefentanyl itself. Like other fentanyl analogues, side effects include itching, nausea, and potentially fatal respiratory depression. Ohmefentanyl has no accepted medical use in most countries and is classified as a Schedule I controlled substance due to its high potential for abuse and lack of safety under medical supervision[1][2][3][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ohmefentanyl.